Articles by Louis Garguilo

  1. Emerging Biopharma – And Their CMOs – Crazy Like A Fox 6/22/2016

    We’re learning of an emerging biopharma and CMO model. We’ll have to see if this evolution, of sorts, takes hold more largely throughout the industry. But then again, we’ve heard “crazy” things in the past that are proving tantalizingly accurate.

  2. Sanofi-Genzyme – And CMOs – Serious About Training Project Managers 6/13/2016

    Carol Sherako, Director Program Management at Sanofi-Genzyme, is a highly trained project manager. She humbly suggests other PMs in the biopharma industry should be, too. If biopharma is going to stick with the model of transitioning scientists from within its ranks to the status of PM, it ought to get serious about training them.

  3. Required Skills For Project Management At Genzyme 6/5/2016

    “I’m not sure you want to hear my thoughts on project management in our industry.” That turns out to be the only statement Carol Sherako, Director Program Management at Sanofi-Genzyme, and I disagreed on in what became two articles of her views on the subject.

  4. For M&A, Shire Stays Three Dimensional With CMOs 5/26/2016

    How do biopharmaceutical companies handle CMO and supplier relationships that stem from M&A activity? Who better to ask than Shire? The folks there know M&A and outsourcing as well as anyone in the global biopharma industry today. 

  5. The Creation Of Shire's Outsourcing Model 5/20/2016

    Approaching $7 billion in annual sales, and fully reliant on outsourcing, no other biopharma today engenders more wonder at its business model than Shire. How does it all fit together? How is it managed? We learn firsthand here.

  6. BioMarin Gives Supplier Scorecards Failing Grades 5/16/2016

    Isaac Young, senior director, supply chain operations, BioMarin Pharmaceutical Inc., gives a lot of today’s CMO/supplier scorecards an “F.” “Stop confusing precision with accuracy,” he says. In this article, he helps us understand how to do better, and provides an example of a scorecard that gets a passing grade.

  7. Trending: Supply Chain Capacity, Value Calculations, And Serialization 5/10/2016

    “Lord knows where this leads over time, but it’s a way of forcing people to think even more strategically about their supply chain,” says Sally, our anonymous supply-chain expert, who also surreptitiously provides some important advice and a unique perspective on three key industry trends.

  8. Some Biopharma Haven't Caught Outsourcing Enthusiasm 5/6/2016

    I often write – and you read – about those individuals at biopharma companies openly enthusiastic about outsourcing. Not too long ago, though, I ran into a person who seemed to outdo the others in absolute embrace of this model. But here’s the catch: Her company won’t allow her enthusiasm to be shared “on the record.”

  9. Amgen's Contagious Relationships Spread Industrywide 5/5/2016

    Amgen is working to spread its supply-chain precepts vertically through the biopharma industry. Rod MacLea is one of those leading the charge. "This knowledge transfer is a big piece we are focusing our efforts on,” he says. “How can we get our industry to look at these ideas and make them mainstream?"

  10. BioMarin Transforms Supplier M&A Into Joint Ventures 4/25/2016

    To navigate supplier and CMO consolidation, Isaac Young, senior director, supply chain operations, BioMarin Pharmaceutical Inc., offers some advice: Approach your outsourcing relationships like joint ventures. “As you have this greater engagement between two companies,” says Young, “you’re likely to enter an interdependent relationship. Why not acknowledge that rather than try to power-play or position one another?”